Page 81 - Fisica In Medicina n° 1/2017

^Äëíê~Åí=jÉÇáÅá= =The role of Stereotactic Body Radiation Therapy (SBRT) in the therapeutic management of isolated metastases from different primitive tumors: a single-institution experienceA. LANCIA, G. INGROSSO, A. CAROSI, E. GIUDICE, S. CICCHETTI, P. MORELLI, C. BRUNI, D. DI CRISTINO, A. MURGIA, A. CANCELLI, I. TURTURICI, A. IADEVAIA, R.SANTONIDepartment of Diagnostic Imaging, Molecular Imaging, Interventional Radiology and Radiotherapy, Tor Vergata University Hospital, Rome, ItalyIntroductionThe oligometastatic state identifies a subset of patients who might be amenable to curative therapy. In this specific group of patients, Stereotactic Body Radiation Therapy (SBRT) has been shown to reach high levels of local tumor control through the delivery of high doses of radiation in few fractions, without the development of significant toxicity. Any meaningful improvement in survival remains debatable.Materials & MethodsFrom July 2007 to March 2016, 78 patients were treated at our Department with Stereotactic Radiotherapy for isolated body metastasis. The most frequent primary tumor was prostate cancer (28.2%), followed by colorectal cancer (23.1%), and lung cancer (20.5%). All patients received a radical treatment to the primary tumor site . Median time from primary tumor treatment to SBRT for oligometastatic disease was 30.3 months (range 1.07-232.3). No patient had synchronous metastases at the time of SBRT. Median age at diagnosis of oligometastatic disease was 70 years (range 47-88). Median Karnofsky Performance Status (KPS) was 90 (range 70-100). Patients were also evaluated in terms of Charlson Comorbidity Score (CCS). The most used SBRT dose72